BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00792558
- Locations
- 🇸🇬
Local Institution, Singapore, Singapore
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00788333
- Locations
- 🇬🇧
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00779428
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00780000
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 371
- Registration Number
- NCT00778622
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00777036
- Locations
- 🇨🇦
Local Institution - 0078, Edmonton, Alberta, Canada
🇺🇸Local Institution - 0028, Seattle, Washington, United States
🇺🇸Seattle Children'S, Seattle, Washington, United States
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00773344
- Locations
- 🇺🇸
Premiere Oncology Of Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Phase IIB Pilot of Atazanavir + Raltegravir
- Conditions
- HIV
- Interventions
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 167
- Registration Number
- NCT00768989
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇫🇷Local Institution, Paris Cedex 20, France
🇺🇸Yale University School Of Medicine, New Haven, Connecticut, United States
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT00767325
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 155
- Registration Number
- NCT00767520
- Locations
- 🇺🇸
The West Clinic, Memphis, Tennessee, United States
🇺🇸Compassionate Cancer Care Medical Group, Inc, Fountain Valley, California, United States
🇺🇸Compassionate Cancer Care Medical Group Inc, Riverside, California, United States